Dosage Regimen Individualization of Acyclovir in Obese Patients with Obesity

The primary objective of the study is to evaluate the **individualization of dosage regimens** for the antiviral medication acyclovir in patients with **obesity**. This is clinically relevant as obesity can significantly alter the pharmacokinetics of medications, potentially affecting their efficacy and safety. Tailoring dosage regimens to the specific needs of obese patients may improve therapeutic outcomes and minimize adverse effects.

The clinical trial focuses on participants diagnosed with **obesity**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed by the sponsor. The absence of specific inclusion or exclusion criteria suggests a broad approach to participant selection, although this cannot be confirmed due to the lack of detailed information.

The clinical trial is designed to evaluate the **individualization of dosage regimens** in patients with **obesity**, specifically focusing on the application to acyclovir. This study is a Phase 3 trial, which is categorized as a controlled, randomized, and double-blind study. The trial commenced on September 1, 2022, and is projected to conclude by April 30, 2024. Participants will be involved in the study for the entire duration unless specific conditions necessitate early termination, such as adverse reactions or non-compliance with the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and ensure adherence to the study protocol. These visits are crucial for collecting data on the efficacy and safety of the individualized dosage regimens. The study will culminate in an end-of-study visit, where final assessments are conducted, and participants are debriefed on the study outcomes.

Throughout the trial, participants are expected to adhere to the study schedule and protocol. Any deviation from the protocol, such as failure to attend scheduled visits or non-compliance with treatment regimens, may result in early termination from the study. The trial aims to provide valuable insights into the optimization of acyclovir dosing in obese patients, potentially leading to improved therapeutic outcomes and personalized treatment strategies.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. Therefore, no further details can be offered in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 1, 2022, with an estimated completion date of April 30, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 3 study, which generally aims to confirm the effectiveness of a treatment in a larger patient population. The absence of detailed endpoints or measurement tools in the data suggests that these elements will be defined in the full trial protocol. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.